TB-500 vs GHK-Cu
Both are repair-focused peptides sold together in our KLOW Blend, but they act at different stages of the repair timeline — one governs whether cells can move to an injury site, the other governs what gets rebuilt once they arrive.
At a Glance
| TB-500 | GHK-Cu | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Molecular class | Synthetic fragment of thymosin beta-4 (a 43-amino-acid parent molecule) | Naturally occurring copper-binding tripeptide (3 amino acids) |
| Discovery timeline | 1981 (parent molecule), actin-binding activity characterized in the early 1990s | Discovered by Dr. Loren Pickart while researching aged liver tissue |
| Primary mechanism studied | Actin regulation, cell migration | Copper-dependent collagen synthesis |
| Common research focus | Tissue repair, regeneration, and wound-healing models | Skin and connective-tissue research, wound healing |
| Human clinical trial data | None for TB-500 itself — a distinct molecule from full-length Thymosin Beta-4's RegeneRx trials | Small-scale human data, but topical (not injectable) only |
| Sold as a blend | Yes — see KLOW Blend and TB-500 + BPC-157 Blend | Yes — see KLOW Blend |
How They Differ
TB-500's research lineage traces to thymosin beta-4, a molecule first studied as part of the immune system before researchers discovered its real significance was as a G-actin-sequestering protein — meaning it directly regulates the cell's cytoskeleton. That mechanism gives TB-500 a structural, mobility-focused role in repair research. See its full discovery history, or how it compares to BPC-157.
GHK-Cu is a naturally occurring peptide-copper complex, first identified during research into why aged liver tissue behaves differently from young tissue. Its research base centers specifically on copper's role as a cofactor in collagen synthesis — the extracellular matrix that gives repaired tissue its structure — which is also why GHK-Cu is one of the few compounds on this site with real (though topical, not injectable) human data. See its full discovery history, or how it compares to KPV and BPC-157.
Why They're Often Studied Together
Because TB-500's cell-migration mechanism and GHK-Cu's collagen-synthesis mechanism act on sequential parts of the repair process — getting repair cells to the injury site, then rebuilding the structural matrix once they're there — researchers studying regenerative pathways often reference both compounds. That's the same rationale behind combining them, alongside BPC-157 and KPV, in the KLOW Blend.
TB-500 vs GHK-Cu questions
Are TB-500 and GHK-Cu studied the same way?
No. TB-500's research base centers on actin regulation and cell migration — a structural, cytoskeletal mechanism. GHK-Cu's research base centers on copper-dependent collagen synthesis and skin biology — a distinct line of literature focused on rebuilding the extracellular matrix, even though both appear together in the KLOW Blend.
Does either have human clinical trial data?
GHK-Cu has small-scale human data, though all of it is from topical (not injectable) application. TB-500 as sold has no completed human trials — it is a distinct molecule from the full-length Thymosin Beta-4 that RegeneRx Biopharmaceuticals tested in human trials, and that clinical data does not directly apply to TB-500 itself.
Does this comparison mean TB-500 and GHK-Cu are approved for a particular use?
No. This page compares TB-500 and GHK-Cu for educational and research context only. Both are sold strictly for laboratory research use and are not evaluated or approved for human or animal use.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.